Ocuphire's end-of-phase 2 meeting with the FDA supports APX3330's phase 3 advancement, with 3-step worsening in binocular DRSS score as the primary endpoint.
A phase 3 trial showed that tarcocimab, a biopolymer with a vascular growth factor antibody, improved vision and anatomical markers in patients with early stage diabetic retinopathy.
THURSDAY, Nov. 9, 2023 (HealthDay News) For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Nov. 3 to 6 in San Francisco. Zeeshan Haq, M.D., from
MALVERN, Pa., Nov. 10, 2023 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today.